PhaseBio Pharmaceuticals, Inc. ( PHAS) Stock. Should you Buy or Sell? $ 1.10
-0.01 (-1.38 %)
PhaseBio Pharmaceuticals, Inc. AnalysisUpdated on 10-09-2022
|Volume Avg.||$326.54 thousand|
|Market Cap||$54.84 M|
|52 Week Range||$0.5 - $4.1|
PhaseBio Pharmaceuticals, Inc. opened the day at $1.10 which is -1.38 % on yesterday's close. PhaseBio Pharmaceuticals, Inc. has a 52 week high of $4.1 and 52 week low of $0.5, which is a difference of $3.6. We like to see positive, upward trending shares, preferably with momentum. Market capitalization is $54.84 M and total net profit is $10831 which means the company is trading at 5063.61 times profit to market capitalization. Theoretically, if you were to buy PhaseBio Pharmaceuticals, Inc. for $54.84 M, it would take 15 years to get your money back. PhaseBio Pharmaceuticals, Inc. are in the Biotechnology space which will have a sweet spot and industry standard for net profit multiples.
PhaseBio Pharmaceuticals, Inc. Stock Forecast - Is PhaseBio Pharmaceuticals, Inc. a Buy or Sell?
|DCF Score||Strong Buy|
|ROA Score||Strong Sell|
Growth and Value
|Net Profit Margin||-2.809|
Valuing PhaseBio Pharmaceuticals, Inc.
|Price Book Value Ratio||-0.461||Price To Book Ratio||-0.461|
|Price To Sales Ratio||-5.409||Price Earnings Ratio||1.925|
How liquid is PhaseBio Pharmaceuticals, Inc.
|Debt Ratio||6.296||Debt Equity Ratio||-1.189|
|Long Term Debt To Capitalization||-0.007||Total Debt To Capitalization||-0.048|
Latest news about PhaseBio Pharmaceuticals, Inc.
PhaseBio Pharmaceuticals (PHAS) delivered earnings and revenue surprises of -3.03% and 91.68%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
PhaseBio Pharmaceuticals (PHAS) delivered earnings and revenue surprises of 65.67% and 98%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
PhaseBio Pharmaceuticals Inc (NASDAQ: PHAS) is voluntarily ending its Phase 2b trial of pemziviptadil (PB1046) in pulmonary arterial hypertension (PAH). The decision follows COVID-19 impacts on manufacturing, associated drug supply, and enrollment rate in the study.
PhaseBio Pharmaceuticals Inc (NASDAQ: PHAS) has announced interim results from the REVERSE-IT Phase 3 trial of bentracimab to reverse the antiplatelet effects of ticagrelor. The trial included patients with urgent surgery or an invasive procedure or experiencing uncontrolled major or life-threatening bleeding.
PhaseBio Pharmaceuticals (PHAS) delivered earnings and revenue surprises of -6.45% and -87.43%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
About PhaseBio Pharmaceuticals, Inc.
PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiovascular diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or an invasive procedure. The company is also developing PB1046, a vasoactive intestinal peptide analogue for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was incorporated in 2002 and is based in Malvern, Pennsylvania.